Reducing serum proinsulin levels in type 2 diabetics

摘要

Provided is the use of an insulin composition including a diketopiperazine in the manufacture of a prandial medicament suitable for administration to a mammalian subject with type 2 diabetes having an elevated proinsulin level, for reducing a risk factor of atherosclerosis in said subject, wherein the medicament is formulated for pulmonary administration, and wherein the medicament is formulated to produce a rapid and early onset of insulin action.